Literature DB >> 33479772

Modulation of Nogo receptor 1 expression orchestrates myelin-associated infiltration of glioblastoma.

Jun-Hee Hong1,2, Sangjo Kang2, Jason K Sa3, Gunwoo Park2, Young Taek Oh4, Tae Hoon Kim2, Jinlong Yin1,5, Sung Soo Kim1, Fulvio D'Angelo4, Harim Koo2,6, Yeonhee You1, Saewhan Park1, Hyung Joon Kwon1, Chan Il Kim1, Haseo Ryu1, Weiwei Lin1, Eun Jung Park1, Youn-Jae Kim7, Myung-Jin Park8, Hyunggee Kim9, Mi-Suk Kim10, Seok Chung11, Chul-Kee Park12, Sung-Hye Park13, Yun Hee Kang14, Jong Heon Kim1, Hideyuki Saya15, Ichiro Nakano16, Ho-Shin Gwak1, Heon Yoo1, Jeongwu Lee17, Eun-Mi Hur18, Bingyang Shi5, Do-Hyun Nam10, Antonio Iavarone19, Seung-Hoon Lee20, Jong Bae Park1,2,5.   

Abstract

As the clinical failure of glioblastoma treatment is attributed by multiple components, including myelin-associated infiltration, assessment of the molecular mechanisms underlying such process and identification of the infiltrating cells have been the primary objectives in glioblastoma research. Here, we adopted radiogenomic analysis to screen for functionally relevant genes that orchestrate the process of glioma cell infiltration through myelin and promote glioblastoma aggressiveness. The receptor of the Nogo ligand (NgR1) was selected as the top candidate through Differentially Expressed Genes (DEG) and Gene Ontology (GO) enrichment analysis. Gain and loss of function studies on NgR1 elucidated its underlying molecular importance in suppressing myelin-associated infiltration in vitro and in vivo. The migratory ability of glioblastoma cells on myelin is reversibly modulated by NgR1 during differentiation and dedifferentiation process through deubiquitinating activity of USP1, which inhibits the degradation of ID1 to downregulate NgR1 expression. Furthermore, pimozide, a well-known antipsychotic drug, upregulates NgR1 by post-translational targeting of USP1, which sensitizes glioma stem cells to myelin inhibition and suppresses myelin-associated infiltration in vivo. In primary human glioblastoma, downregulation of NgR1 expression is associated with highly infiltrative characteristics and poor survival. Together, our findings reveal that loss of NgR1 drives myelin-associated infiltration of glioblastoma and suggest that novel therapeutic strategies aimed at reactivating expression of NgR1 will improve the clinical outcome of glioblastoma patients.
© The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  glioblastoma; myelin-associated infiltration; nogo receptor; radiogenomics

Mesh:

Substances:

Year:  2021        PMID: 33479772     DOI: 10.1093/brain/awaa408

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  4 in total

1.  Go, cancer stem cell, go! CSCs overcome myelin inhibition to move within white matter pathways.

Authors:  Daniel J Silver; Justin D Lathia
Journal:  Brain       Date:  2021-03-03       Impact factor: 15.255

Review 2.  Regional Development of Glioblastoma: The Anatomical Conundrum of Cancer Biology and Its Surgical Implication.

Authors:  Ciro De Luca; Assunta Virtuoso; Michele Papa; Francesco Certo; Giuseppe Maria Vincenzo Barbagallo; Roberto Altieri
Journal:  Cells       Date:  2022-04-15       Impact factor: 7.666

3.  PTEN inhibits AMPK to control collective migration.

Authors:  Florent Peglion; Lavinia Capuana; Isabelle Perfettini; Laurent Boucontet; Ben Braithwaite; Emma Colucci-Guyon; Emie Quissac; Karin Forsberg-Nilsson; Flora Llense; Sandrine Etienne-Manneville
Journal:  Nat Commun       Date:  2022-08-11       Impact factor: 17.694

4.  Pro-inflammatory cytokines in cystic glioblastoma: A quantitative study with a comparison with bacterial brain abscesses. With an MRI investigation of displacement and destruction of the brain tissue surrounding a glioblastoma.

Authors:  Bjørnar Hassel; Pitt Niehusmann; Bente Halvorsen; Daniel Dahlberg
Journal:  Front Oncol       Date:  2022-07-29       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.